Silverback Therapeutics/$SPRY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Silverback Therapeutics
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Ticker
$SPRY
Sector
Primary listing
Employees
165
Headquarters
Website
SPRY Metrics
BasicAdvanced
$900M
-
-$0.49
0.92
-
Price and volume
Market cap
$900M
Beta
0.92
52-week high
$18.90
52-week low
$9.08
Average daily volume
2.4M
Financial strength
Current ratio
6.172
Quick ratio
5.838
Long term debt to equity
37.973
Total debt to equity
38.28
Profitability
EBITDA (TTM)
-58.733
Gross margin (TTM)
80.87%
Net profit margin (TTM)
-42.74%
Operating margin (TTM)
-52.82%
Effective tax rate (TTM)
-0.60%
Revenue per employee (TTM)
$680,000
Management effectiveness
Return on assets (TTM)
-13.85%
Return on equity (TTM)
-23.56%
Valuation
Price to revenue (TTM)
7.924
Price to book
4.68
Price to tangible book (TTM)
5.02
Price to free cash flow (TTM)
-14.622
Free cash flow yield (TTM)
-6.84%
Free cash flow per share (TTM)
-0.623
Growth
Revenue change (TTM)
22,367.80%
Earnings per share change (TTM)
5.48%
3-year revenue growth (CAGR)
259.94%
3-year earnings per share growth (CAGR)
-13.52%
What the Analysts think about SPRY
Analyst ratings (Buy, Hold, Sell) for Silverback Therapeutics stock.
Bulls say / Bears say
The US FDA expanded neffy's label to include patients weighing 15–30 kg, opening access to about 2 million more school-aged children and is expected to accelerate prescriptions during peak seasons (Reuters turn5news13)
As of December 31, 2024, ARS had $314 million in cash, cash equivalents, and short-term investments, supporting operations for at least three years (Refinitiv turn3search2)
In the first quarter of 2025, net product revenue was $7.8 million, with over 5,000 doctors prescribing neffy, highlighting strong early demand in the market (Nasdaq turn7search0)
High SG&A and R&D expenses compared to neffy revenue are limiting profitability: in Q1 2025, SG&A reached $41.1 million while neffy net product revenue was $7.8 million (Nasdaq turn7search0)
An antitrust lawsuit against AptarGroup claims monopolistic control over key nasal spray components, which could disrupt production and increase costs (Reuters turn5news12)
Technical indicators point to overbought conditions, and analyst price targets vary from $28 to $40, indicating potential downside volatility from current price levels (Investing.com turn0search2)
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
SPRY Financial Performance
Revenues and expenses
SPRY Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Silverback Therapeutics stock?
Silverback Therapeutics (SPRY) has a market cap of $900M as of October 26, 2025.
What is the P/E ratio for Silverback Therapeutics stock?
The price to earnings (P/E) ratio for Silverback Therapeutics (SPRY) stock is 0 as of October 26, 2025.
Does Silverback Therapeutics stock pay dividends?
No, Silverback Therapeutics (SPRY) stock does not pay dividends to its shareholders as of October 26, 2025.
When is the next Silverback Therapeutics dividend payment date?
Silverback Therapeutics (SPRY) stock does not pay dividends to its shareholders.
What is the beta indicator for Silverback Therapeutics?
Silverback Therapeutics (SPRY) has a beta rating of 0.92. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.